)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals (524731) investor relations material
Jenburkt Pharmaceuticals Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary5 May, 2026
Executive summary
Standalone audited financial statements for the quarter and year ended 31st March 2026 were approved, with the auditor issuing an unmodified opinion on the results.
A final dividend of ₹20.70 per equity share (207% of face value) was recommended for FY 2025-26.
The 41st Annual General Meeting is scheduled for 4th September 2026 via video conferencing.
Appointment and re-appointment of Shri Dilip H. Bhuta as Director and Whole Time Director & CFO for a five-year term from April 2027 were approved.
Financial highlights
Revenue from operations for FY 2025-26 was ₹17,904.00 lakhs, up from ₹15,841.25 lakhs year-over-year.
Net profit after tax for FY 2025-26 was ₹3,473.60 lakhs, compared to ₹3,206.06 lakhs in the previous year.
Earnings per share (EPS) for FY 2025-26 stood at ₹78.71, up from ₹72.65 year-over-year.
Total comprehensive income for FY 2025-26 was ₹3,320.70 lakhs.
Cash and cash equivalents at year-end were ₹557.71 lakhs, down from ₹736.48 lakhs at the previous year-end.
Outlook and guidance
The auditor’s report notes no material uncertainty regarding the company’s ability to meet its liabilities as they fall due within one year from the balance sheet date.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jenburkt Pharmaceuticals
- Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731
Q3 25/263 Feb 2026 - Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/2521 Nov 2025
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/2521 Nov 2025
- Q3 FY25 saw higher revenue, profit, and EPS, with clean auditor review and pharma focus.524731Q3 24/2521 Nov 2025
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/2628 Oct 2025
- Revenue and profit after tax rose year-over-year, with EPS reaching ₹17.66.524731Q1 25/2612 Aug 2025
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/256 Jun 2025
Next Jenburkt Pharmaceuticals earnings date
Q1 26/2711 Aug, 2026
Jenburkt Pharmaceuticals
Next Jenburkt Pharmaceuticals earnings date
Q1 26/2711 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage